POLICYBZR Q3 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹871 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
PB Fintech delivered a landmark Q3 FY24 with PAT of INR 37 crores, achieving full-year breakeven target within first nine months—a swing of INR 482 crores from prior year loss. Core marketplace revenue grew 39% YoY to INR 593 crores, driven by health and term insurance (44% YoY). Total insurance premium ARR reached INR 17,000 crores, with renewal trail ARR at INR 454 crore (up from INR 317 crore). Adjusted EBITDA improved by INR 50 crore for the quarter, consistent with INR 150-200 crore annual improvement guidance. New initiatives turned contribution-positive with 56% advisor growth and presence across 17,000+ PIN codes. Paisabazaar credit growth moderated to 30-36% due to partner recalibration around RBI guidance, though long-term 2x-3x industry growth target remains. Health insurance new business carries zero contribution but generates 4x NPV multiple, creating near-term margin pressure but long-term value. Management guided to INR 1,000 crore PAT by FY27. Key risk: unsecured credit regulatory tightening could extend beyond one quarter, and health's negative first-year contribution will pressure margins as mix increases.
Colored figures show movement against the previous available record.
Guidance to track
- Management reaffirmed commitment to INR 1,000 crore PAT by FY2027, building on FY24 PAT positive achievement ahead of schedule.
- Paisabazaar expects 10% growth delta reduction (from 40% to ~30%) for next quarter due to unsecured credit partner recalibration, normalizing afterward.
- ESOP charges to decline from INR 330-350 crore to ~INR 100 crore as IPO-related grants vest. This represents normalized future compensation cost.
- Company has grown adjusted EBITDA by more than INR 50 crore per quarter for 6-7 quarters, on track for INR 200 crore+ annual improvement through revenue growth and operating leverage.
Risks flagged
- Sachin questioned whether structural changes are needed in Paisabazaar given Policybazaar's scaled growth. Management acknowledged active strategic review without specifics.
- RBI guidance on unsecured credit causing partner portfolio reviews and tightening of approval logics. Growth reduced by 10% delta. Recovery dependent on partner recalibration timeline, creating near-term headwind.
- Health insurance new business has zero contribution in year 1 but 4x NPV multiple over lifetime. Higher health mix (growing >50% YoY) creates margin pressure in current period results. Yashish estimated 2% margin drag vs normalized results.
- Despite strong cash generation and no major acquisition plans, management deferred capital return decisions. Alok indicated plans exist 'in mind' but not board-approved, creating uncertainty for investors expecting near-term shareholder回报.
Key quotes
- We had aimed for a full year PAT breakeven in the financial year 2024, and very happy to announce that we've already achieved that within the first three quarters, with the strongest quarter yet to follow.
- Our incremental revenue and our Adjusted EBITDA. Incremental Adjusted EBITDA is 34% of the incremental revenue. That probably gives you some indication of the minimum that we can achieve.
- Health makes up... no, no, but even in the other products, there is a 15% extra that comes because of renewal business. In health, I'm telling you, in the, on the new business, if you look at it, we'll have a significantly negative EBITDA margin. At the contribution itself, it is zero.
Research modules